High Court wrongly concluded public interest in cheaper drugs overrode patent holder rights, appeal court rules
There was ‘nothing unlawful’ in Biogen’s application for and exploitation of a parent patent
There was ‘nothing unlawful’ in Biogen’s application for and exploitation of a parent patent
Giving doctors access to breakthrough medicines is priority for Biogen boss Michael O’Connell in his role as Irish Pharmaceutical Healthcare Association president
Trials showed €25,000 a year drug slowed rate of cognitive decline in patients with early Alzheimer’s by 27% compared to a placebo.
Congressional report says assessment of Biogen drug was ‘rife with irregularities’
Pharma companies sought to prevent sale of generic multiple sclerosis drug
Investors await more data on company’s new Alzheimer’s disease drug
Incoming Ipha president says industry expects to bring 30 new medicines to market in Ireland next year but warns on patent protection
Future of Aduhelm was in doubt after Medicare restricted coverage to clinical trials
Markets report: Cairn soars 7.2 per cent on pledge to return €95m to investors this year
Tech boom leads Wall Street indices to record highs
Corporation tax generated €11.8 billion in receipts last year, €1 in every €5 collected
EMA vote deals a setback to controversial $56,000-a-year treatment
Software-as-a-Service company also reports surge in third quarter revenues
Luxury goods groups Richemont and LVMH among standout performers
Strong results from Swiss group boost food stocks, offsetting losses elsewhere
Company will pay over money within seven days of formal agreement being signed
Tax dispute dates back to a 2016 audit by Revenue
Ratings agency turns negative on outlook for ‘over-the-counter’ medicines group over potential debt burden
ECB pledges to keep interest rates at record lows for even longer
Business interview: CEO Murray Kessler talks Covid and sorting out Perrigo’s Irish tax bill
Revenue Commissioners and Perrigo have been in intense discussions for months
Fallout from controversial approval of Alzheimer’s drug is a concern
A decision by the US FDA to approve aducanumab has alarmed many experts
Bank shares suffer as bond yields tighten
Market edgy ahead of ECB policy decision and US inflation data
Medical community sharply divided on the benefits of this drug in treating dementia
Price over double the highest industry analyst estimate triggers renewed criticism
Many scientists opposed approval of controversial treatment, saying it did not work
Consumer healthcare group hit with largest tax assessment ever issued by commissioners
Amount is second-largest in the history of the State, behind only high-profile Apple case
Irish-founded firm is listed on Toronto Stock Exchange but is run from Limerick
Billionaire investor’s Berkshire Hathaway sinks $5.7bn into four US pharma stocks
Investors hope a gridlock in US congress would be able to stall major policy changes
Aducanumab targets clumps of protein that can build up in the brain
Crosswords & puzzles to keep you challenged and entertained
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices